Baker Bros. Advisors’s Regulus Therapeutics RGLS Stock Holding History

Baker Bros. Advisors’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,694,044	Closed	-$4.71M	–	97
2025 Q1	$4.71M	Buy	+2,694,044	New	+$3.55M	0.05%	58

Other funds holding RGLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Baker Bros. Advisors's RGLS Position: Q2 2025 in Review

Baker Bros. Advisors sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 2,694,044 shares — an estimated $4.71M sold.

Baker Bros. Advisors first reported a position in RGLS in Q1 2025 and held it in 1 quarter. The position peaked at $4.71M in Q1 2025. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.

Baker Bros. Advisors reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
Baker Bros. Advisors sold 2,694,044 Regulus Therapeutics shares in Q2 2025, an estimated $4.71M.
Baker Bros. Advisors first reported a position in Regulus Therapeutics in Q1 2025 and held it in 1 quarter.
Baker Bros. Advisors's Regulus Therapeutics position peaked at $4.71M in Q1 2025.
0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.

Based on Baker Bros. Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.